The aim of the study is to evaluate after 4 to 6 months the effects of a GLP-1 analog treatment on psoriatic skin lesions in patients with type 2 diabetes.
The objective of this study is to analyse short and medium-term efficacy on clinical, immunological and histopathological parameters of a GLP-1 receptor agonist on moderate to severe psoriasis plaques in a group of patients with type 2 diabetes.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
GLP-1 analog treatment
Cliniques universitaires Saint-Luc
Brussels, Belgium
Improvement of PASI score
Time frame: 4 to 6 months
Evolution of BMI (body mass index)
number of patients with weight loss
Time frame: 4 to 6 months
Evolution of immunological data
cytokines and T cells
Time frame: 4 to 6 months
Evolution of histopathological data
thickness, dermis infiltrate in skin plaques and in control areas
Time frame: 4 to 6 months
Evolution of glycaemic control
HbA1c
Time frame: 4 to 6 months
Evolution of routine laboratory measures
number of participants with biological adverse effects (pancreatitis enzymes)
Time frame: 4 to 6 months
Evolution of BMI
weight
Time frame: 4 to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.